There is a growing need for agents that stabilize blood vessels in serious clinical conditions such as diabetic eye disease and cancer where vascular leak and pathologic angiogenesis drive disease progression.
Rocco Rotello, Ph.D., associate professor of pharmaceutical sciences at Cedarville University, has entered into an agreement with Aerpio Therapeutics, a new clinical-stage biopharmaceutical company based in Cincinnati, Ohio, to work on a novel biological approach to stabilize blood vessels.
“It’s gratifying to have the opportunity to contribute to developing a novel therapeutic with potential to treat important diseases,” Rotello said.
Rotello, who previously worked for 16 years at Procter & Gamble Pharmaceuticals, brought his expertise to Cedarville University in summer 2011. Currently he contributes to the school of pharmacy’s research and professional course development. He is among the first to use Cedarville’s newly constructed state-of-the-art Health Sciences Center for academic research.
Located in southwest Ohio, Cedarville University attracts 3,400 undergraduate, graduate and online students to more than 100 areas of study. Celebrating 125 years of inspiring greatness, Cedarville is a Christ-centered learning community recognized nationally for rigorous academic programs, strong graduation and retention rates, accredited professional and health science offerings and leading student satisfaction ratings.
Visit the University online at www.cedarville.edu.
